Hepatitis B minor triple positive patients need to undergo quantitative testing of Hepatitis B virus DNA (HBV-DNA), so as to determine their infectiousness and guide the application of antiviral drugs. HBV-DNA quantitative test is to detect the content of hepatitis B virus in the blood, and currently, HBV-DNA molecular hybridization spot test is mostly used to directly detect HBV-DNA in the serum, and its reference value is <1000 copies/mL. If the result of HBV-DNA test is >normal value, it means that the content of hepatitis B virus in the body is high, the virus replication is active, and the infectiousness is high; we can also choose appropriate antiviral drugs, such as entecavir, tenofovir, etc., according to the high and low levels of the virus, as well as evaluating the effect of antiviral drug treatment. It is recommended that patients with Hepatitis B Minor Triple Positive should seek medical consultation as early as possible and be treated after systematic evaluation to avoid delaying their condition.